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Abstract
Background: 14-3-3ơ is an intracellular, phosphoserine binding protein and proposed to be involved in
tumorigenesis. However, the expression dynamics of 14-3-3ơ and its clinicopathological/prognostic significance in
human tumors are still controversial.
Methods: The method of immunohistochemistry (IHC) and Western blot were utilized to examine the protein
expression of 14-3-3ơ in gastric cancer and paired normal adjacent gastric mucosal tissues. Receive operating
characteristic (ROC) curve analysis was employed to determine a cutoff score for 14-3-3ơ expression in a training
set (n = 66). For validation, the ROC-derived cutoff score was subjected to analysis of the association of 14-3-3ơ
expression with patient outcome and clinical characteristics in a testing set (n = 86) and overall patients (n = 152).
Results: The expression frequency and expression levels of 14-3-3ơ were significantly higher in gastric cancer than
in normal gastric mucosal tissues. Correlation analysis demonstrated that high expression of 14-3-3ơ in gastric
cancer was significantly correlated with clinical stage and tumor invasion. Furthermore, in the testing set and
overall patients, Kaplan-Meier analysis showed that elevated 14-3-3ơ expression predicted poorer overall survival
(OS) and progression-free survival (PFS). Importantly, high 14-3-3ơ expression was also associated with shortened
survival time in stage III and stage IV gastric cancer patients. Multivariate analyses revealed that 14-3-3ơ expression
was an independent prognostic parameter in gastric cancer.
Conclusions: These findings provide evidence that high expression of 14-3-3ơ may be important in the tumor
progression and servers as an independent molecular marker for poor prognosis of gastric cancer. Thus,
overexpression of 14-3-3ơ identifies patients at high risk and is a novel therapeutic molecular target for this tumor.
Background
Gastric cancer is one of the most common causes of
cancer-related death worldwide [1], especially in East
Asian countries such as China, Japan [2]. In 2005, there
were approximately 0.4 million new cases and 0.3 mil-
lion deaths from gastric cancer in China [3]. Despite
recent advances in surgical techniques and medical
treatment, the overall 5-year survival rate of gastric
cancer in China remains low at about 40%. Many stu-
dies have demonstrated that multiple genetic alterations,
including tumor suppressor genes, oncogenes, cell adhe-
sion molecules, cell-cycle regulators, and growth factors,
are responsible for the development and progression of
gastric cancer [4]. Studies have unraveled many aber-
rantly expressed genes in gastric cancer including BMI1
[5], COX-2 [6], HER3 [7], RKIP and STAT3 [8], SPARC
[9] and HER2 [10,11], which make risk assessment of
gastric cancer patients more accurately. However, pro-
mising molecules that have clinicopathological/prognos-
tic significance in gastric cancer remain substantially
limited. It is necessary to further understand the mole-
cular mechanisms involved in gastric cancer and to
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only improve poorer prognosis but also provide novel
promising therapy targets.
14-3-3 proteins are a family of about 30 kD dimeric
highly-conserved proteins and ubiquitously expressed in
all eukaryotic organisms [12]. There are seven closely
related genes (b, g, ε, h, ζ, ơ,τ) in 14-3-3 family proteins.
These genes often form heterodimers or homodimers
and bind to over 100 different protein ligands [13,14].
Thus, 14-3-3 proteins are involved in many different
cellular signaling processes including cell proliferation,
cell cycle control, apoptosis and malignant transforma-
tion [14,15]. Among the seven isotypes, 14-3-3ơ was ori-
ginally characterized as a human mammary epithelium
marker 1 (HME1) and identified as a tumor suppress
gene [12,16]. Growing evidences showed that 14-3-3ơ
was significantly decreased or lost due to silencing of
the gene via hypermethylation in several solid tumors
[17-22]. Previous reports found that decreased expres-
sion of 14-3-3ơ predicted a poor survival in breast and
nasopharyngeal cancer [23,24]. However, contradictory
with the tumor suppressor role of 14-3-3s, overexpres-
sion of 14-3-3ơ in pancreatic cancer cell led to drug
resistance, cell migration and invasion [25]. Further-
more, high expression of 14-3-3s was an independent
prognostic factor for poor survival in pancreatic and col-
orectal cancer [26,27]. Thus, the biological role of 14-3-
3ơ in tumorigenesis and progression of various types of
human cancers varies depending on specific tumor type.
Here, we selected the gastric cancer specimens with
strict protocol to detect 14-3-3ơ expression dynamics
and analyze their clinicopathological/prognostic
significances.
Methods
Patients
A total of 216 primary gastric cancer patients from the
archives of the Department of Pathology in the Third
and Second Affiliated Hospital of Sun Yat-Sen Univer-
sity (Guangzhou, China) were initially recruited in our
study. All patients underwent initial surgical resection
from March 2001 to January 2006. We further
screened patients using a strict eligibility criteria proto-
col as follows: microscopically confirmed adenocarci-
noma of the stomach; without any metastatic diseases;
no prior chemotherapy or radiation therapy history;
receiving unified regimen as first-line chemotherapy
after resection of primary tumors (we unified as FOL-
FOX regimen: fluorouracil, leucovorin and oxaliplatin),
and no radiation treatment being administered to any
of the patients; having over 5-year follow up period.
Ultimately, 52 patients with loss of follow-up and 12
patients with deficiency in clinical characteristics were
excluded from this study, leading to 152 gastric cancer
patients subjecting to further clinical and survival ana-
lysis. In details, the overall cohort consisted of 105
male and 47 female with the median age of 58.0 year
(range, 27 - 81 year). 103 patients were censused as
death during the 5 years of follow-up time, including 5
cases died from postoperative complications and 98
cases died from tumor progression. Of the overall
patients, 66 patients were randomly assigned by com-
puter (SPSS 17.0 software) to the training set, and
remaining 86 patients werer a n d o m l ya s s i g n e dt ot h e
testing set. Clinicopathological variables of the two
cohorts, such as age, gender, clinical stage, tumor inva-
sion, node stage, and histology differentiation, were
included in this study. All tumors were classified and
staged according to the revised guidelines advocated by
the International Union against Cancer. We obtained
prior patients’ consent and approval from the Institute
Research Ethics Committee of Sun Yat-Sen University
for the use of clinical materials described in the pre-
sent study.
Tissue microarray construction
The tissue microarrays (TMAs) were constructed as a
method described previously by Xie et al [28]. Briefly,
the paraffin-embedded tissue blocks and the corre-
sponding histological hematoxylin and eosin-stained
slides were overlaid for TMA sampling. Interested core
tissue biopsies (0.6-mm in diameter) were punched from
representative tumor areas and from adjacent gastric
mucosa tissue from blocks of individual donor tissue
using a trephine (triplicate cylinders from carcinoma tis-
sue and one cylinder from normal adjacent gastric
mucosa tissue). The tissue cylinders were then trans-
ferred into a recipient paraffin block at defined positions
by using a tissue-arraying instrument (Beecher Instru-
ments, Silver Spring, MD, USA).
Immunohistochemical analysis and evaluation
The TMAs slides were deparaffinized in xylene, rehy-
drated through graded alcohol, immersed in 3% hydro-
gen peroxide for 10 min to block endogenous
peroxidase activity, and antigen retrieved by pressure
cooking for 3 min in Tris/EDTA (pH = 8.0). Then the
slides were incubated with the primary antibody of 14-
3-3s (monoclonal mouse; 1:50; Santa Cruz, SC-100638)
for 1 hour at room temperature. After being incubated
with the secondary antibody for 30 min, specimens were
stained with DAB (3, 3-diaminobenzidine). Finally, the
sections were counterstained with hematoxylin, dehy-
drated and mounted. A negative control was obtained
by replacing the primary antibody with a normal murine
IgG. Known immunostaining-positive colorectal carci-
noma slides were used as positive controls as previously
reported [27].
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considered as positive staining. We scored the staining
intensity as follows: 0, no staining; 1+, mild staining; 2+,
moderate staining; 3+, intense staining. The area of
staining was evaluated as follows: 0, no staining of cells
in any microscopic fields; 1+, < 30% of tissue stained
positive; 2+, between 30% and 60% stained positive; 3+,
> 60% stained positive. 14-3-3s expression was evalu-
ated by combined assessing of staining intensity and
extension. The minimum score when summed (intensity
+ extension) was 0, and the maximum was 6. The cri-
teria used in this study has been widely accepted pre-
viously [24]. Expression of 14-3-3s was assessed and
scored by two independent pathologists (Drs. F Tang
and ZY Feng) who were blinded to the clinicopathologi-
cal data. The agreement of these two pathologists on
the IHC score reached to 84% (128 identical scores in
total 152 cases), suggesti n go u rs c o r i n gs y s t e mw a s
highly solid and reproducible. If the results reported by
the two pathologists were consistent, the value was
selected. However, the interobserver disagreements
(approximately 6% of total cases) were reviewed for a
second time, followed by a conclusive judgment by both
pathologists.
Western blot analysis
The gastric cancer and paired normal adjacent gastric
mucosal tissues were ground and lysed with the RIPA
buffer on ice before being subjected to Western blot
analysis. The protein concentration was detected by
the Bradford method with BSA (Sigma-Aldrich) as the
standard. Equal amounts of cell and tissue extract (40
μg) were subjected to SDS-PAGE and transferred to
nitrocellulose membrane (Bio-Rad) for antibody blot-
ting. The membrane was then blocked and incubated
with mouse anti-glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) antibody (Abmart, #M20006) and
mouse anti-14-3-3s antibody (Santa Cruz, SC-
100638).
Selection of cutoff score for 14-3-3s “positive” expression
The ROC curve analysis was subjected to the selection
of 14-3-3s cutoff score in the training set, as described
previously [29]. Briefly, the sensitivity and specificity
for the outcome being studied at each score was
plotted to generate a ROC curve. The score localized
closest to the point at both maximum sensitivity and
specificity, the point (0.0, 1.0) on the curve, was
selected as the cutoff score leading to the greatest
number of tumors which were correctly classified as
having or not having the outcome. To facilitate ROC
curve analysis, the survival features were dichotomized:
survival (death VS. others (censored, alive or death
from other causes)).
Follow up
All patients had follow-up records for over 5 years.
After the completion of therapy, patients were observed
at 3 month intervals during the first 3 years and at 6
month intervals thereafter. Overall survival was defined
as the time from diagnosis to the date of death or when
censused at the latest date if patients were still alive.
Progression-free survival was defined as the time from
diagnosis to the date of local failure/distant metastasis
or the date of death or when censused at the latest date.
Statistical analysis
For survival analysis, optimal cutpoint for 14-3-3s
expression was obtained by ROC analysis in the training
set (n = 66). For validation, the relationships between
14-3-3s expression, which was classified by ROC analy-
sis-generated cutoff point,a n dO S ,P F Sw e r ee v a l u a t e d
in the testing set (n = 86) and overall patients (n = 152).
The chi-square test or Fisher’s exact test was employed
to evaluate the relationship between 14-3-3s expression
and clinicopathological variables. The multivariate Cox
proportional hazards model was utilized to estimate the
hazard ratios and 95% confidence intervals for patient
outcome. The relationships between 14-3-3s expression
and OS, PFS were determined by Kaplan-Meier analysis.
The log-rank tests were performed to value the differ-
ence in survival probabilities between patient subsets.
All p values quoted were two-sided and p <0 . 0 5w a s
considered statistically significant. Statistical analysis was
performed using SPSS v. 17.0 (SPSS, Inc, Chicago, IL).
Results
14-3-3s expression in gastric cancer and normal gastric
mucosal tissues
14-3-3s was detected in the cytoplasm and overex-
pressed in the gastric cancer (Figure 1A and 1A’),
whereas normal paired gastric mucosal tissues showed
nearly negative expression (Figure 1B and 1B’). Consis-
tent with this result, Western blot analysis revealed a
similar finding in gastric cancer and normal adjacent
gastric mucosal tissues (Figure 1C).
To further assess survival analysis and avoid the pro-
blems of multiple cutpoint selection, ROC curve analysis
was employed to determine cutoff score for 14-3-3s
expression. As shown in Figure 2A and 2B, the 14-3-3s
cutoff score for OS and PFS in the training set was 3.25 (p
< 0.001) and 3.35 (p = 0.003) respectively. We thus selected
a 14-3-3s expression score of 3 (> 3 VS. ≤ 3) as the uni-
form cutoff point for survival analysis in the testing set.
14-3-3s expression and clinical features
The clinical features of these two cohorts of patients,
including age, gender, clinical stage, tumor invasion, node
stage, histology differentiation, 14-3-3s expression, were
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of 3 in the training set successfully segregated the testing
set into high (44/86, 51.2%) and low (42/86, 48.8%) 14-3-
3s expression subgroups. High expression of 14-3-3s was
mainly found in more advanced tumor stages (77/107 in
stage III+IV VS. 12/45 in stage I+II, p = 0.004). Further-
more, correlation analysis demonstrated that high 14-3-3s
expression was correlated with clinical stage (p < 0.001 for
both set) and tumor invasion (p < 0.001 for training set
and p = 0.005 for testing set) in both sets. 14-3-3s asso-
ciated to patients’ age in the testing set (p = 0.01) but not
in the training set. We failed to detect any relationship
between 14-3-3s with other patient characteristics, includ-
ing gender, node stage, and histology differentiation.
14-3-3s expression and survival analysis: univariate
survival analysis
A ss h o w ni nF i g u r e3 Aa n d3 C ,K a p l a n - M e i e ra n a l y s i s
showed that elevated 14-3-3s expression strongly
predicted an inferior OS in the testing set (p < 0.001)
and overall patients (p < 0.001). Moreover, 14-3-3s
expression was also a powerful prognostic factor for PFS
in the testing set (p < 0.001, Figure 3B) and overall
patients (p < 0.001, Figure 3D). Considering the poor
outcome in late-stage gastric cancer, further analysis
was performed with regard to 14-3-3s expression in
A
GAPDH
14-3-3ı
T       N       T       N       T       N
B
A’
B’
C
Figure 1 14-3-3s expression in human primary gastric cancer
and normal adjacent gastric mucosal tissue. (A) 14-3-3s was
detected in the cytoplasm and overexpressed in the gastric cancer
tissue (100 ×). (B) Adjacent non-neoplastic gastric mucosal tissue
showed nearly negative expression of 14-3-3s (100 ×). (A’), (B’)
demonstrated the higher magnification (400 ×) from the area of the
box in (A) and (B) respectively. (C) Western blot analysis of 14-3-3s
expression in representative primary gastric cancer tissue (T) and
normal adjacent mucosal tissue (N). Equal loading of protein was
determined by GAPDH.
Figure 2 Receiver operating characteristic (ROC) curves
analysis of 14-3-3s cutoff score in the training set. (A) 14-3-3s
cutoff point for overall survival in the training set. (B) 14-3-3s cutoff
point for progression-free survival in the training set. At each
immunohistochemical score, the sensitivity and specificity for the
outcome being studied was plotted, thus generating a ROC curve.
14-3-3s cutoff score for overall survival, progression-free survival was
3.25 and 3.35 respectively.
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The results demonstrated that compared with 14-3-3s
low expression, high expression of 14-3-3s showed a
significant trend toward worse OS and PFS in gastric
cancer patients of stage III (p =0 . 0 0 1f o rO Sa n dp =
0.017 for PFS, Figure 4A and 4B) and stage IV (p <
0.001 for OS and p = 0.001 for PFS, Figure 4C and 4D).
Results in the overall patients were similar to those
found in the testing set (Figure 4E-H).
Multivariate Cox regression analysis
To avoid the influence caused by univariate analysis, the
expression of 14-3-3s as well as other parameters was
examined in multivariate Cox analysis (Table 2 and Table
3). In the testing set, 14-3-3s was indeed found to be a sig-
nificant independent prognostic factor for poor OS (hazard
ratio, 4.527; 95% CI, 2.274-9.012; p < 0.001; Table 2) and
PFS (hazard ratio, 3.582; 95% CI, 1.717-7.475; p = 0.001;
Table 2). Similar results were also observed in overall
patients (hazard ratio, 5.161; 95% CI, 2.990-8.909; p <0 . 0 0 1
for OS and hazard ratio, 4.416; 95% CI, 2.482-7.856; p <
0.001 for PFS; Table 3). Of other parameters, clinical stage
was found to be an independent prognostic factor for
patient survival in the testing set but not in overall patients.
Discussion
Gastric cancer is one of the most common cancers
worldwide and it poses one of the most serious public
health problem [1]. Recurrence and metastasis are still
the major issues for the poor survival of advanced gas-
tric cancer patients [30]. Although previous studies have
found that many aberrant expressed genes in gastric
tumor can help classify the risk of patient outcome
[5-11], more novel molecular markers that can identify
tumor progression and predict the prognosis individually
are still urgently needed. The 14-3-3 family proteins
have gained much attention over the past years due to
their involvement in cancers by regulation of diverse
cellular processes [14,15]. Among the seven isoforms,
14-3-3s is up-regulated by p53 in response to DNA
damage, and sequesters the essential mitotic initiation
complex, cdc2-cyclin B1, from entering the nucleus,
thus preventing the initiation of mitosis [31]. As a result,
14-3-3s induces G2 arrest and allows DNA damage
repair. Thus, different from other members of the
family, 14-3-3s is defined as a negative regulator of cell
cycle checkpoints and a potential tumor-suppressor pro-
tein [12]. However, the biological role of 14-3-3ơ in
tumorigenesis and progression of various types of
human tumors remains controversial. Here, to further
reveal the biological function of 14-3-3ơ in gastric can-
cer, we studied 14-3-3ơ expression dynamics and ana-
lyzed their clinicopathological/prognostic significances
in 152 tumor specimens.
In this study, to develop an objective 14-3-3s cutoff
point for survival analysis, we used the ROC curve
Table 1 Association of 14-3-3s expression with patient’s characteristics in primary gastric cancer
Variable All cases Training set (n = 66) Testing set (n = 86)
High
expression
Low
expression
p
a High
expression
Low
expression
p
a
Age (years)
≥ 58.00
b 83 25(30.1%) 13(15.7%) 0.627 29(34.9%) 16(19.3%) 0.010
< 58.00 69 20(29.0%) 8(11.6%) 15(21.7%) 26(37.7%)
Gender
Male 105 29(27.6%) 16(15.2%) 0.340 31(29.5%) 29(27.6%) 0.887
Female 47 16(34.0%) 5(10.6%) 13(27.7%) 13(27.7%)
Clinical stage
I + II 45 6(13.3%) 12(26.7%) 0.000 6(13.3%) 21(46.7%) 0.000
III + IV 107 39(36.4%) 9(8.4%) 38(35.5%) 21(19.6%)
Tumor invasion
T1+T2 23 0(0%) 7(30.4%) 0.000 3(13.0%) 13(56.5%) 0.005
T3+T4 129 45(34.9%) 14(10.9%) 41(31.8%) 29(22.5%)
Node stage
N0+N1 101 32(31.7%) 15(14.9%) 0.979 24(23.8%) 30(29.7%) 0.105
N2+N3 51 13(25.5%) 6(11.8%) 20(39.2%) 12(23.5%)
Histology-differentiation
Well 51 15(29.4%) 11(21.6%) 0.123 11(21.6%) 14(27.5%) 0.395
Poorly 101 31(30.7%) 10(9.9%) 33(32.7%) 28(27.7%)
a x
2 test
b median age
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Page 5 of 10analysis to generate a cutoff score in the training set. 14-
3-3s expression, which was classified as high and low
level by the ROC-derived cutoff point, was mainly found
to be higher in more advanced tumor stages (stage III
and IV), indicating that 14-3-3s might be involved in
gastric cancer progression. Correlation analysis further
demonstrated that high 14-3-3s expression was asso-
ciated with clinical stage and tumor invasion in gastric
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Figure 3 Kaplan-Meier survival analysis of 14-3-3s expression in the testing set and overall patients. (A) Higher 14-3-3s expression was
closely correlated with poor overall survival and (B) progression-free survival in the testing set. (C) Patients with higher 14-3-3s expression also
acquired an inferior overall survival and (D) progression-free survival in overall patients. In the testing set and overall patients, the median
duration of overall survival for patients with low and high expression of 14-3-3s was 73.0 VS. 17.0 months (p < 0.001) and 73.0 VS. 14.0 months
(p < 0.001), respectively.
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Figure 4 Kaplan-Meier survival analysis of 14-3-3s expression in subsets of gastric cancer patients with stage III and IV (log-rank test).
(A) Probability of overall survival and (B) progression-free survival of patients with stage III gastric cancer in the testing set: low expression, n =
17; high expression, n = 26; (C) Probability of overall survival and (D) progression-free survival of stage IV patients with gastric cancer in the
testing set: low expression, n = 5; high expression, n = 11. (E) Probability of overall survival and (F) progression-free survival of patients with
stage III gastric cancer in the overall patients: low expression, n = 22; high expression, n = 55; (G) Probability of overall survival and (H)
progression-free survival of stage IV patients with gastric cancer in the overall patients: low expression, n = 9; high expression, n = 21.
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Page 7 of 10cancer (Table 1). Furthermore, in the testing set and
overall patients, high 14-3-3ơ expression predicted a sig-
nificant OS and PFS disadvantage over low 14-3-3ơ
expression subgroup (Figure 3). Importantly, worse
prognostic impact of increased 14-3-3s expression was
demonstrated in patients with stage III and IV tumors
(Figure 4), indicating that 14-3-3ơ might be a novel fac-
tor for risk definition in gastric cancer. In addition, mul-
tivariate analyses in the testing set and overall patients
revealed that 14-3-3ơ expression was an independent
prognostic parameter. Taken together, our findings in
this study provided evidence that elevated expression of
14-3-3s in gastric cancer might facilitate an increased
malignant and worse prognostic phenotype of this
tumor.
With regard to the prognostic impact of 14-3-3s in
different human cancers, some of the reported data are
totally contradictory. It was documented that loss
expression of 14-3-3s was linked to a poor prognosis of
patients with breast and nasopharyngeal cancers [23,24].
However, consistent with the results found in pancreatic
and colorectal carcinomas [26,27], our finding in this
study showed that high expression of 14-3-3s was posi-
tively associated with clinic stage and poor survival. The
underlying mechanism(s) of 14-3-3s to impact cancer
prognosis might be depended on intrinsic properties of
the tumor type. Moreover, different co-expression of 14-
3-3s and other molecules [24], as well as the nature of
the therapeutic regimen in various types of human can-
cers [32], which further make us to understand that the
function of 14-3-3s and its underlying mechanism(s) to
impact cancer prognosis may be tumor-type specific.
Recently, studies have showed that overexpression of
14-3-3s is correlated with tumor metastasis and pro-
gression in pancreatic [25], breast [33] and ovarian can-
cer cells [34], which may further explain our findings
Table 2 Results of multivariate Cox proportional-hazards analysis in testing set
Variable For death For progression-free survival
Hazard Ratio 95%
confidence interval
p Hazard Ratio 95%
confidence interval
p
Age < 58.00
years (VS. ≥ 58 years)
1.101 0.637 to 1.902 0.731 1.056 0.577 to 1.936 0.859
Gender Male
(VS. Female)
0.772 0.408 to 1.461 0.427 1.049 0.525 to 2.094 0.892
Clinical stage
IV + III (VS. II +I)
3.391 1.156 to 9.949 0.026 5.220 1.529 to 17.823 0.008
Tumor invasion
T4 +T 3 (VS. T2 +T 1)
1.066 0.320 to 3.553 0.917 0.730 0.206 to 2.585 0.626
Nodal stage N3 +N 2
(VS. N1 +N 0)
0.705 0.387 to 1.282 0.251 0.735 0.373 to 1.448 0.373
Differentiation
Low (VS. High)
0.862 0.437 to 1.701 0.668 0.936 0.442 to 1.982 0.863
14-3-3s
Positive (VS. Negative)
4.527 2.274 to 9.012 0.000 3.582 1.717 to 7.475 0.001
Table 3 Results of multivariate Cox proportional-hazards analysis in overall patients
Variable For death For progression-free survival
Hazard Ratio 95%
confidence interval
p Hazard Ratio 95%
confidence interval
p
Age < 58.00
years (VS. ≥ 58 years)
1.046 0.701 to 1.562 0.825 1.036 0654 to 1.642 0.880
Gender Male
(VS. Female)
0.713 0.474 to1.073 0.105 0.733 0.409 to 1.278 0.165
Clinical stage
IV + III (VS. II +I)
0.988 0.500 to1.952 0.972 1.355 0.558 to 3.121 0.476
Tumor invasion
T4 +T 3 (VS. T2 +T 1)
2.175 0.896 to 5.278 0.086 1.432 0.547 to 3.747 0.465
Nodal stage N3 +N 2
(VS. N1 +N 0)
1.056 0.681 to1.638 0.808 1.243 0.751 to 2.059 0.397
Differentiation
Low (VS. High)
0.765 0.470 to1.243 0.279 0.810 0.478 to1.375 0.463
14-3-3s
Positive (VS. Negative)
5.161 2.990 to 8.909 0.000 4.416 2.482 to 7.856 0.000
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Page 8 of 10that higher 14-3-3s expression is mainly detected in
more advanced tumor stages and also identified as a
poor prognosis indicator in late-stage gastric cancer
patients. Hence, our study demonstrated that 14-3-3s
was an independent prognostic biomarker for OS and
PFS in gastric cancer. Especially, overexpression of 14-3-
3s was relevant with tumor progression. The findings
reported here could have clinical value in predicting the
prognosis of gastric cancer and identifying gastric cancer
patients that are at high risk of progression and
recurrence.
Conclusion
In summary, in this study, we describe 14-3-3s expres-
sion in gastric cancer and normal gastric mucosal tis-
sues. Our results provide a basis for the concept that
increased expression of 14-3-3s in human gastric cancer
may be important in the tumor progression and serves
as an independent biomarker for poor survival. Thus,
overexpression of 14-3-3ơ identifies patients at high risk
and is a novel therapeutic molecular target for gastric
cancer.
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